Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The p53 protein, a crucial tumor suppressor, is frequently inactivated in human cancers.
• Inactivation often occurs via mutation or interaction with the MDM2 oncoprotein.
• Targeting the p53-MDM2 interaction is a promising anticancer strategy.

Purpose of the Study:

• To detail the methodologies employed in identifying small-molecule inhibitors of the MDM2-p53 interaction.
• To provide an overview of techniques used in the drug discovery process for this target.

Main Methods:

• High-throughput screening assays to identify initial hit compounds.
• Structure-based drug design utilizing structural information of the p53-MDM2 complex.
• Lead optimization through medicinal chemistry to improve potency and pharmacokinetic properties.

Main Results:

• Successful identification of small molecules that inhibit the MDM2-p53 interaction.
• Several inhibitors have advanced to clinical trials for cancer treatment.

Conclusions:

• The described methods are effective for discovering novel inhibitors of the MDM2-p53 interaction.
• This approach holds significant potential for developing new cancer therapeutics.